Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1377121 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $136.84Day +0.94%Mkt cap $8.8B1Y +143.2%Off 52W high −4.5%Vol (1Y) 52.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,498 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest12.9% of sh out |
| Days to cover9.5d |
| 13F net flow (QoQ)+9.80% |
| Top-10 13F concentration56.4% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$74.1M |
| Earnings (TTM)-$114.7M |
| ROE−20.2% |
| Net margin−282.8% |
| ROIC−23.5% |
| Sales growth 3Y20.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+56.7% |
| 1Y+143.2% |
| 3Y+616.8% |
| 5Y+191.2% |
| Since incept. (ann.)+28.0% |
Total return through 2026-07-28 · series begins 2016-08-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)52.0% |
| Ann. volatility (3Y)55.1% |
| Sharpe (1Y)2.00 |
| Sharpe (3Y)1.47 |
| Max drawdown (1Y)−16.4% |
| Max drawdown (3Y)−31.6% |
| Beta (3Y vs SPY)0.66 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 9.8M | $1.0B | — | +0.7% |
| FARALLON CAPITAL MANAGEMENT LLC | 6.3M | $669M | — | +3.3% |
| UBS Group AG | 5.2M | $546M | — | +86.9% |
| RTW INVESTMENTS, LP | 5.1M | $533M | — | +0.0% |
| WELLINGTON MANAGEMENT GROUP LLP | 3.6M | $379M | — | +13.5% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.5M | $367M | — | new |
| STATE STREET CORP | 3.1M | $329M | — | −2.6% |
| JANUS HENDERSON GROUP PLC | 2.9M | $305M | — | +9.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding suppressed: the summed institutional 13F holdings (79,332,570) exceed the latest reported shares-outstanding count (64,311,373) by more than securities-lending double counting can explain (FINRA short interest 7,540,996 shares at 2026-04-30), so the share count is stale or wrong (common for annual 20-F foreign private issuers after a share issuance) and a percentage would be fabricated. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | $0.05 | — | $56.4M | +99.0% |
| 2025-12-31 | 2026-02-25 | — | — | $7.4M | −95.6% |
| 2025-09-30 | 2025-11-06 | −$0.62 | — | $4.7M | +0.8% |
| 2025-06-30 | 2025-08-06 | −$0.55 | — | $5.5M | +33.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
